

# Resource Summary Report

Generated by [NIF](#) on Aug 11, 2026

## BD Biosciences: LSRFortessa Cell Analyzer

RRID:SCR\_018655

Type: Tool

### Proper Citation

BD Biosciences: LSRFortessa Cell Analyzer (RRID:SCR\_018655)

### Resource Information

**URL:** <https://www.bdbiosciences.com/en-us/instruments/research-instruments/research-cell-analyzers/lrfortessa>

**Proper Citation:** BD Biosciences: LSRFortessa Cell Analyzer (RRID:SCR\_018655)

**Description:** BD LSRFortessa system can be configured with up to 7 lasers, blue, red, violet, UV and yellow-green. The instrument can accommodate the detection of up to 18 colors simultaneously with defined set of optical filters that meet or exceed the majority of today's assay requirements. BD FACSDiva software controls the efficient setup, acquisition, and analysis of flow cytometry data from the BD LSRFortessa workstation. The software is common across BD FACS instrument families, including the BD FACSCanto cell analyzer and BD FACSAria cell sorter systems.

**Synonyms:** BD LSRFortessa

**Resource Type:** instrument resource

**Keywords:** Flow cytometer, BD flow cytometer, multicolor flow cytometry assay, cell analysis, cell analyzer, laser, detect colors simultaneously, instrument, equipment

**Specification URL:** [https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR\\_018655.pdf](https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/main/PDF/SCR_018655.pdf)

**Resource Name:** BD Biosciences: LSRFortessa Cell Analyzer

**Resource ID:** SCR\_018655

**Alternate IDs:** SCR\_01960, SCR\_019601, SCR\_019602, SCR\_019600, Model\_Number\_LSRFortessa, SCR\_019605

**Record Creation Time:** 20220129T080341+0000

**Record Last Update:** 20260811T043620+0000

---

## Ratings and Alerts

No rating or validation information has been found for BD Biosciences: LSRFortessa Cell Analyzer.

No alerts have been found for BD Biosciences: LSRFortessa Cell Analyzer.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 75 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [NIF](#) .

Suresh V, et al. (2026) Modelling EWS::FLI1 protein fluctuations reveal determinants of tumor plasticity in Ewing sarcoma. EMBO molecular medicine, 18(2), 646.

Nelson MC, et al. (2026) MicroRNA-146a Protects against Hepatocellular Carcinoma through Suppression of CCL5. Cancer research communications, 6(2), 359.

Ullrich L, et al. (2026) Protocol for multiplexed detection of antibody binding to cell-surface-expressed hemagglutinin by flow cytometry. STAR protocols, 7(2), 104614.

Zhou Z, et al. (2026) Using an Unbiased Coexpression Network to Reveal Cross-Talking Pathways of Phosphoinositide-3-Kinase Regulatory Subunit 1 in Skin Aging and Rejuvenation. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 40(2), e71466.

Choudhury PR, et al. (2026) Atorvastatin pre-exposure in hypercholesterolemia remedies 27HC mediated dendritic cell dysfunctions in triple-negative breast cancer. Molecular therapy. Oncology, 34(3), 201250.

Heiduk M, et al. (2026) Nectin-4 reduces T cell effector function and is a therapeutic target in pancreatic cancer. JCI insight, 11(2).

Anderko RR, et al. (2026) Pancreatic Cancer Organoids Recapitulate Chemotherapy Response and Identify a Potent Cytotoxic T-Cell Population. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(3), 596.

Maerz MD, et al. (2026) BCG vaccination induces antibacterial effector functions among V $\alpha$ 1/3 T cells that are associated with protection against tuberculosis. Cell reports. Medicine, 102536.

Tian M, et al. (2026) Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. Cell reports. Medicine, 7(7), 102922.

Sun W, et al. (2026) Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. *Cell reports. Medicine*, 7(3), 102644.

Wu P, et al. (2026) A circRNA neoantigen vaccine elicits potent antitumor immunity and synergizes with checkpoint blockade in melanoma. *Cancer letters*, 648, 218459.

Lohbihler M, et al. (2026) Human pluripotent stem cell-derived atrioventricular node-like pacemaker cells exhibit biological conduction bridge properties. *Cell stem cell*, 33(4), 571.

Guilz NC, et al. (2026) Autosomal dominant CDC45 deficiency with allelic expression bias causes a novel genetic disease of the immune system. *bioRxiv : the preprint server for biology*.

Fahmy AM, et al. (2026) STING dampens the unfolded protein response to enable the presentation of self-antigens on MHC-I during inflammation. *Cell reports*, 45(6), 117497.

Guercio BJ, et al. (2026) Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(8), 1434.

Tang E, et al. (2026) Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy. *Cancer immunology research*, 14(8), 1292.

Weber PAA, et al. (2026) Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control. *Cancer research communications*, 6(7), 1619.

Ma T, et al. (2025) Pan-Cancer Analyses Refine the Single-Cell Portrait of Tumor-Infiltrating Dendritic Cells. *Cancer research*, 85(19), 3596.

Boccardo S, et al. (2025) Dynamics of tissue repair regulatory T cells and damage in acute *Trypanosoma cruzi* infection. *PLoS pathogens*, 21(1), e1012906.

Bischoff ME, et al. (2025) Copper Drives Remodeling of Metabolic State and Progression of Clear Cell Renal Cell Carcinoma. *Cancer discovery*, 15(2), 401.